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London Hospital NHS Trust, London, UKIntroduction: IgG4-related disease (IgG4-RD) is a relapsing multisystem ﬁbro-inﬂammatory disease, which
may involve the kidney (IgG4-related kidney disease [IgG4-RKD]) and retroperitoneum (IgG4-related
retroperitoneal ﬁbrosis [IgG4-RPF]). The aim of this study was to describe IgG4-RKD and IgG4-RPF in
the United Kingdom.
Methods: We conducted a retrospective observational study of patients with IgG4-RKD and IgG4-RPF in a
multicenter IgG4-RD cohort. Data were collected through review of medical records. We describe clinical
parameters at baseline, histological and radiological ﬁndings, treatment, and patient outcomes.
Results: Of 154 patients with IgG4-RD, 14 (9.1%) had IgG4-RKD, 10 (6.5%) had IgG4-RPF, and 4 (2.6%) had
both. Patients were aged 58.2  14.2 years, and 26 (92.9%) were male. Creatinine at presentation was
worse in those with intrinsic renal disease (229 mmol/l vs. 110 mmol/l; P ¼ 0.0076). Serum IgG4 was elevated
in the majority of patients (87.5%), and hypocomplementemia was present in half of those with IgG4-RKD.
Fifteen patients underwent renal biopsy; tubulointerstitial nephritis with abundant IgG4þ plasma cells was
the most common ﬁnding (n ¼ 14; 93.3%), and 4 (26.7%) patients had membranous nephropathy. Most
patients (89.3%) were treated with corticosteroids, and 4 (16.0%) with additional azathioprine as initial
management. Thirteen patients (46.4%) relapsed over 60  48 months of follow-up, at median 18 (12–36)
months after renal/RPF diagnosis; 61.5% of relapses were in the kidney. Renal function deteriorated in 5
patients (20.8%), including 2 (8.3%) who reached end-stage renal disease (ESRD).
Conclusion: IgG4-RKD and IgG4-RPF represent major organ manifestations of IgG4-RD, and should be
identiﬁed early with prompt treatment to prevent progression to ESRD.
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NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).I gG4-RD is a recently recognized multisystem diseasecharacterized by lymphoplasmacytic inﬂammation
and ﬁbrosis in affected tissues.1,2 It can affect almost
any organ system in the body.3 Renal involvement may
manifest as an intrinsic kidney disease (IgG4-RKD) or as
a consequence of ureteric obstruction from retroperito-
neal ﬁbrosis (IgG4-RPF). Intrinsic kidney disease is most
commonly a tubulointerstitial nephritis (IgG4-TIN), butspondence: Rhys D.R. Evans, UCL Centre for Nephrology,
Free Hospital, Pond Street, London NW3 2QG, UK. E-mail:
evans@ucl.ac.uk
ved 29 June 2018; revised 15 August 2018; accepted 27
t 2018; published online 1 September 2018may also present with a variety of glomerular lesions,
in particular membranous nephropathy, or through
abnormalities on renal imaging such as multiple low-
density lesions or diffusely enlarged kidneys.4,5 Organ-
speciﬁc diagnostic criteria have been proposed, including
Raissian criteria for IgG4-TIN.6 IgG4-RD is responsive to
immunosuppressive therapies, but delays in diagnosis
and disease relapse lead to a risk of permanent organ
damage including progression to end-stage renal disease
(ESRD).6–8 Early recognition of IgG4-RKD, and its distinc-
tion from other multisystem diseases that affect the kid-
ney, is therefore important.
Cohorts of patients with IgG4-RKD and IgG4-RPF have
been reported in North America6,9 and Asia,7,8,10–14 butKidney International Reports (2019) 4, 48–58
RDR Evans et al.: IgG4-Related Kidney Disease in the UK CLINICAL RESEARCHthe features of renal involvement in Europe are yet to be
described. We undertook this study to describe the
clinical characteristics and outcomes of renal and retro-
peritoneal involvement in a cohort of IgG4-RD patients
from the United Kingdom (UK).
METHODS
Study Design and Setting
We conducted a retrospective observational study of
patients with IgG4-RD managed at the John Radcliffe
Hospital, Oxford, University College London Hospital,
and the Royal Free Hospital, London, UK. These centers
provide tertiary care to patients with IgG4-RD, and a
prospective LondonOxford database of IgG4-RD pa-
tients was established in 2010. The IgG4-RD service
was set up by gastroenterologists, with an initial focus
on hepatobiliary and pancreatic disease, but now care
is provided to patients with multisystem disease by
specialists in the full range of organ systems affected
by IgG4-RD, including rheumatologists, nephrologists,
oral medicine and respiratory physicians, histopathol-
ogists, radiologists, and surgeons. Patients with IgG4-
RD are referred from local, regional, and national
hospitals, and video-linked multidisciplinary team meet-
ings are held every 6 weeks between the London and
Oxford groups. Patients with autoimmune pancreatitis,
IgG4-sclerosing cholangitis, IgG4-related lung disease, and
1 patient with IgG4-RPF in this cohort have previously
been reported.15–17
Participants and Deﬁnitions
All adult patients (aged >18 years) with a diagnosis of
IgG4-RD between 2002 and 2018 in the
LondonOxford cohort were included. Diagnosis of
IgG4-RD was made according to recognized diagnostic
criteria,18 consensus histological criteria,19 and/or or-
gan speciﬁc diagnostic criteria, as appropriate.6,20
Patients were identiﬁed with renal and retroperito-
neal involvement according to the following deﬁni-
tions: (i) renal involvement (IgG4-RKD): a renal biopsy
result consistent with IgG4-RD (IgG4-TIN fulﬁlling the
Raissian criteria,6 or biopsy-proven membranous ne-
phropathy if IgG4-RD has been diagnosed at another
site); or IgG4-RD diagnosed at another organ site and
renal imaging consistent with IgG4-RKD (multiple low-
density lesions or diffusely enlarged kidneys on
computed tomography [CT], or renal uptake on posi-
tron emission tomographycomputed tomography
[PET-CT] without other obvious cause); (ii) retroperi-
toneal involvement (IgG4-RPF): RPF biopsy consistent
with IgG4-RD (according to consensus criteria19), or
IgG4-RD diagnosed at another site and RPF (periaortic
or periureteral) on imaging (with or without ureteric
obstruction).Kidney International Reports (2019) 4, 48–58Data Collection
Demographic and clinical data were collected in pa-
tients with IgG4-RKD and IgG4-RPF from the
LondonOxford database, and by further review of
medical records. This included gender, age at diag-
nosis, medical comorbidities, other IgG4-RD organ
involvement, laboratory parameters at presentation,
and radiological ﬁndings. Renal biopsy results were
recorded, including glomerular and tubulointerstitial
abnormalities on light microscopy, immunohistochem-
istry including details of IgG4 staining, and electron
microscopy. Fibrosis was characterized as storiform in
nature if collagen ﬁbers were radially arranged in a
whorled pattern that seemed to weave through the
tissue.1 The opinion of the reporting renal pathologist
and/or reviewing pathologist at the specialist IgG4-RD
multidisciplinary team was taken to describe histolog-
ical features. We documented patient management
including details of immunosuppression, as well as
renal and patient outcomes (response to treatment,
relapse, development of ESRD and its management, and
mortality) during follow-up. Progressive renal impair-
ment was deﬁned as >15% reduction in estimated
glomerular rate (eGFR) from baseline. Complete response
in membranous nephropathy was deﬁned as resolution of
proteinuria (<300 mg/d, or protein:creatinine <30mg/
mmol, or urine dipstick trace or negative for protein).
Relapsed IgG4-RD was a clinical diagnosis based on the
consensus opinion of the multidisciplinary team (e.g.,
deterioration in renal function or in liver function tests
without other obvious cause in a patient with known
IgG4-RKD or IgG4-related hepatobiliary disease, respec-
tively). A structured vignette (Supplementary Table S1)
describing presentation, investigation, and management
was prepared for each case.
Outcome Measures and Statistical Analysis
We determined the prevalence of renal and retroperi-
toneal involvement in the LondonOxford cohort. We
performed a descriptive analysis of demographic and
clinical parameters at baseline, radiology ﬁndings,
histological ﬁndings in patients with IgG4-RKD, treat-
ment, and renal and patient outcomes. Variables are
presented as number and percentage, mean and SD, or
median and interquartile range (IQR), depending on
data distribution. We compared variables in patients
with intrinsic renal disease (with or without RPF) to
those with RPF (without intrinsic renal disease) using
the Student t test and MannWhitney test if contin-
uous, and using tests of proportionality (c2 or Fisher
exact) if categorical. We also compared rates of IgG4-
RD relapse and renal outcomes (progressive renal
impairment or not) between patients maintained on
immunosuppression, and those patients on no or49
Table 1. Demographic details, inclusion criteria, and baseline
clinical data
Parameter Entire cohort
Intrinsic
renal disease
No intrinsic
renal disease P value
Number of patients 28 18 10
Demographic data
Age, mean (SD) 58.2 (14.2) 57.0 (12.4) 60.3 (17.6) 0.57
Male, n (%) 26 (92.9) 17 (94.4) 9 (90.0) 0.99
Criteria for renal and RPF involvementa
Renal biopsy consistent with
IgG4-RD
13
IgG4-RD diagnosed at other
site and renal imaging
abnormalities consistent
with IgG4-RD
5
RPF biopsy consistent with
IgG4-RD
4
IgG4-RD diagnosed at other
site and RPF on imaging
6
Other organ involvement, n (%)b
Pancreas 17 (60.7) 10 (55.6) 7 (70.0) 0.69
Biliary tree 7 (25.0) 6 (33.3) 1 (10.0) 0.36
Liver 3 (10.7) 2 (11.1) 1 (10.0) 0.99
Salivary gland 6 (21.4) 5 (27.8) 1 (10.0) 0.37
Lymph nodes 6 (21.4) 3 (16.6) 3 (30.0) 0.63
Lung 5 (17.9) 2 (11.1) 3 (30.0) 0.32
eGFR, estimated glomerular ﬁltration rate; IgG4-RD, IgG4-related disease; RPF, retro-
peritoneal ﬁbrosis.
aFor those with both renal and RPF, reason for inclusion given as per renal criteria.
bOther organ involvement aside from above: intestinal ¼ 3, thyroid ¼ 1, pituitary ¼ 1,
neuropathy ¼ 1, cardiac ¼ 1.
CLINICAL RESEARCH RDR Evans et al.: IgG4-Related Kidney Disease in the UKminimal immunosuppression (prednisolone #5 mg/d and
no steroid-sparing agent). All analyses were conducted
using GraphPad Prism version 7 (https://www.graphpad.
com) with a P value <0.05 considered to represent
statistical signiﬁcance.
RESULTS
Prevalence of IgG4-RKD and IgG4-RPF
Of 154 patients with IgG4-RD, 28 patients (18.2%) had
renal or retroperitoneal involvement (Figure 1). Four-
teen patients (9.1%) had intrinsic renal disease, 10
(6.5%) had RPF, and 4 (2.6%) had both intrinsic renal
disease and RPF.
Demographic and Clinical Characteristics at
Baseline
Demographic details, basis of renal/RPF involvement,
and other IgG4-RD organ involvement are outlined in
Table 1. The mean age of the patients with IgG4-RKD
and IgG4-RPF was 58.2  14.2 years, and 26 patients
(92.9%) were male. In all, 25 patients (89.2%) had
other organ involvement of IgG4-RD. A total of 18
patients (64.3%) had comorbid medical disease. Most
common comorbidities were hypertension (n ¼ 12,
43%), diabetes mellitus (n ¼ 7, 25%), ischemic heart
and cerebrovascular disease (n ¼ 5, 18%), and
obstructive airways disease (n ¼ 3, 11%). Either IgG4-
RKD or IgG4-RPF was part of the initial presentation of
IgG4-RD in 20 patients (71.4%), whereas in the other
patients it represented relapsed disease in patients with
a pre-existing diagnosis of IgG4-RD.
Laboratory Parameters at Presentation
Laboratory parameters at presentation are outlined in
Table 2. Serum IgG and IgG4 levels were elevated in 13
(52%) and 21 (87.5%) patients at diagnosis, respectively.
Serum creatinine was higher (229 mmol/l vs. 110 mmol/l,
P ¼ 0.0076) and eGFR lower (27.9 ml/min per 1.73 m2 vs.
60.9 ml/min per 1.73 m2, P ¼ 0.011) in patients with
intrinsic renal disease compared to those without. Com-
plement C3 or C4 was low in 6 patients (50.0% of those in
whom it was measured) with IgG4-RKD.UK cohort of IgG4-RD, n = 154
Renal and/or retroperitoneal involvement, n = 28 (18.2%)
Intrinsic renal disease,
n  = 14 (9.1%)
Retroperitoneal 
fibrosis, n = 10 (6.5%)
Intrinsic renal disease 
and retroperitoneal 
fibrosis, n = 4 (2.6%) 
Figure 1. Cohort description.
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Modalities used for renal and retroperitoneal imaging
were as follows: computed tomography (CT) (n ¼ 19;
67.9%); ultrasound (n ¼ 7; 25.0%); positron emission
tomographycomputed tomography (PET-CT) (n¼5;
17.2%); and magnetic resonance imaging (MRI) (n ¼ 5;
17.9%). Para-aortic or peri-ureteric RPF was evident in 14
patients (50%). This was associated with ureteric
obstruction in 6 patients (21.4%) (bilateral in 1, unilateral
in 5). Eleven patients (61.1%) with IgG4-RKD had ab-
normalities on imaging; multiple low-density lesions were
found in 8 patients (44.4%) patients and diffusely
enlarged kidneys in 4 patients (22.2%) (1 patient had
both features) (Figure 2 for representative images).
Histopathology
In all, 15 patients with IgG4-RKD underwent renal biopsy
(Table 3; Figure 3 for representative images); 14 patients
(93.3%) had tubulointerstitial nephritis, which was asso-
ciated with glomerular disease in 3 cases (20.0%), and 1
patient (6.7%) had glomerular disease alone, without
associated tubulointerstitial inﬂammation. Membranous
nephropathy was the cause of glomerular disease in all
cases.
All patients with TIN had a lymphoplasmocytic
inﬁltrate with ﬁbrosis. The ﬁbrosis was described as
“storiform” in 1 specimen; the remaining 13 specimens
had ﬁbrosis according to the reporting renal pathologistKidney International Reports (2019) 4, 48–58
Table 2. Laboratory parameters at presentation
Parameter Entire cohort (n [ 28)
Intrinsic renal
disease (n [ 18)
No intrinsic renal
disease (n [ 10) P valuea Data missing
Proteinuria (1þ or greater on dipstick;
or protein:creatinine >30 mg/mmol), n (%)c
8 (53.3) 8 (57.1) 0 (0.0) NR 13
eGFR (ml/min per 1.73 m2)b, median (IQR) 40.2 (25.8–69.4) 27.9 (22–44) 60.9 (39.6–83.8) 0.01 1
Creatinine, mmol/l, median (IQR) 163 (102–238) 229 (157–275) 110 (86–139) 0.008 1
Urea, mmol/l, mean (SD) 11.2 (6.0) 13.3 (7.1) 8.6 (3.2) 0.09 8
Serum IgG4 elevated, n (%)c 21 (87.5) 14 (93.3) 7 (77.8) 0.53 4
Absolute IgG4, g/l, median (IQR)d 2.9 (2.1–5.9) 3.0 (2.6–6.7) 2.4 (1.3–5.7) 0.39 5
IgA, g/l, mean (SD) 2.2 (1.1) 2.1 (1.6) 2.4 (0.9) 0.61 4
IgM, g/l, mean (SD) 1.1 (1.1) 1.3 (1.3) 0.8 (0.2) 0.23 4
IgG, g/l, mean (SD) 15.6 (7.9) 16.3 (8.6) 14.5 (7.5) 0.59 3
Low C3, n (%)c 6 (42.8) 5 (41.7) 1 (50.0) NR 14
Low C4, n (%)c 5 (35.7) 4 (33.3) 1 (50.0) NR 14
ANA positive, n (%)c 6 (30.0) 5 (35.7) 1 (16.7) 0.61 8
ANCA positive, n (%)c 1 (5.8) 1 (8.3) 0 (0.0) 0.99 11
ESR, median (IQR) 28 (16–82) 29 (17–82) 24 (11.5–62.5) 0.50 9
CRP, mean (SD) 40.4 (80.0) 8.8 (10.0) 72 (106) NR 13
ANA, antinuclear antibody; ANCA, antineutrophil cytoplasmic antibody; CRP, C-reactive protein; eGFR, estimated glomerular ﬁltration rate; ESR, erythrocyte sedimentation rate; IQR,
interquartile range; NR, not recorded.
aComparisons are made only between the groups for parameters with data available in >50% of patients in both groups.
bThe eGFR was calculated using the Modification of Diet in Renal Disease (MDRD) equation (ethnicity unadjusted).
cPercentages are given out of the number of patients who had data collected for that parameter.
dDue to a change in assay used to measure serum IgG4 at 1 site, 2 baseline IgG4 levels have normal range of 0.04 to 0.86 g/l; all other samples have normal range of 0.1 to 1.3 g/l.
RDR Evans et al.: IgG4-Related Kidney Disease in the UK CLINICAL RESEARCHbut were not all re-reviewed for a speciﬁc pattern of
ﬁbrosis by the IgG4-RD multidisciplinary team. One pa-
tient with IgG4-RPF had obliterative phlebitis; repre-
sentative histology is shown in Figure 4. In 13 of 14
patients (92.9%) with TIN, IgG4 staining demonstrated
>10 IgG4þ plasma cells per high-power ﬁeld (in the most
concentrated area), and all these patients fulﬁlled the
Raissian criteria for IgG4-TIN.6 One patient (patient 3)
had advanced interstitial ﬁbrosis and did not fulﬁll the
IgG4-TIN criteria (IgG4-RD diagnosed in the pancreas).
Assessment of tubular basement membrane immune de-
posits occurred in 4 patients; 3 of these patients (75%)
had evidence of immune complex deposition.
Treatment
A total of 25 patients (89.3%) were treated with immu-
nosuppression, whereas 3 patients (10.7%) were managed
without immunosuppression. All patients who were on
immunosuppressive treatment received tapering prednis-
olone at a mean starting dose of 40 16 mg/d. One patient
was pulsed with 3 doses of i.v. methylprednisolone prior
to starting oral prednisolone. Four patients (16.0%) were
treated with a steroid-sparing agent as part of initial
treatment alongside prednisolone; azathioprine was used
in all of these patients. Five patients (35.7%) with IgG4-
RPF underwent ureteric stenting, and 1 patient (7.1%)
underwent surgical ureterolysis.
Relapse
The mean follow-up duration was 60  48 months.
Thirteen patients (46.4%) with IgG4-RKD and IgG4-
RPF had a relapse at any site after initial treatmentKidney International Reports (2019) 4, 48–58(10 [55.6%] if intrinsic renal disease and 3 [30.0%] if
no intrinsic renal disease, P ¼ 0.25). Relapse occurred
at median of 18 (IQR, 12–36) months after renal/RPF
diagnosis. Relapse occurred in 9 patients (56.3%) on
no or minimal immunosuppression, and in 4 patients
(33.3%) on maintenance immunosuppression (P ¼
0.28). The sites of relapsed disease were the kidney
(n ¼ 8, 61.5%), retroperitoneum (n ¼ 2, 15.4%),
hepatopancreatobiliary system (n ¼ 2, 15.4%), and
peripheral nervous system (peripheral neuropathy)
(n ¼ 1, 7.7%).
All patients with relapse were treated with immu-
nosuppression. Twelve patients (92.3%) had steroids
restarted or the dose escalated, and 7 patients (53.8%)
had a steroid-sparing agent added (mycophenolate
mofetil in 3 patients, azathioprine in 3 patients, and
rituximab in 1 patient).
Renal and Patient Outcomes
Four patients who had incomplete follow-up data were
excluded from the outcome analysis. In patients with
complete data (n ¼ 24), improvement was seen in renal
function overall with the latest and presenting median
eGFR 59 ml/min per 1.73 m2 (IQR, 37–75) and 40.5 ml/
min per 1.73 m2 (IQR, 26–70), respectively (P ¼ 0.23),
and median creatinine 114 mmol/l (IQR, 98–165) and
162 mmol/l (IQR, 102–237) (P ¼ 0.057). In addition,
reductions in serum IgG4 levels were observed; latest
serum IgG4 was 1.6 g/l (IQR, 0.6–2.5) compared to 2.8
g/l (IQR, 2.1–5.7) at presentation (P ¼ 0.026). In pa-
tients with IgG4-RKD, latest eGFR was 53 ml/min per
1.73 m2 (IQR, 35–65) compared to 27.9 ml/min per 1.7351
Figure 2. Representative imaging of IgG4-related kidney disease (IgG4-RKD) and IgG4-related retroperitoneal ﬁbrosis (IgG4-RPF). (a) Computed
tomography images of multiple low density renal lesions in IgG4-RKD. (b) Positron emission tomographycomputed tomography (PET-CT) image
of left-sided ureteric obstruction and hydronephrosis in IgG4-RPF. (c) Axial PET-CT image of retroperitoneal ﬁbrosis in IgG4-RPF. (d) Sagittal
PET-CT images of presacral retroperitoneal inﬂammation in IgG4-RPF.
CLINICAL RESEARCH RDR Evans et al.: IgG4-Related Kidney Disease in the UKm2 (IQR, 22–42) at presentation (P ¼ 0.057), and latest
creatinine 125 mmol/l (101–166) compared to 229 mmol/l
(IQR, 160–272) at presentation (P ¼ 0.048) (Figure 5).
Renal function was stable or improved in 19 pa-
tients (79.2%); 5 patients (20.8%) had progressive
deterioration in renal function, including 2 (8.3%)
who reached ESRD, 1 of whom underwent renal
transplantation. Progressive renal disease occurred in
4 patients (25.0%) with intrinsic renal disease and in
1 patient (11.1%) with RPF (P ¼ 0.62). Of those who
progressed (patient numbers 4, 13, 15, 18, and 25;
Supplementary Table S1), 3 patients progressed off
immunosuppression (patient 13 relapsed shortly after
stopping steroid, patient 15 was lost to follow-up and
represented off immunosuppression with near-ESRD,
and patient 25 was treated conservatively, given
frailty); 1 patient progressed on low-dose immuno-
suppression (patient 18, 2 mg/d prednisolone); and 1
patient progressed despite steroid-sparing therapy
(patient 4, azathioprine 100 mg/d). Overall, progres-
sion occurred in 1 patient (9.1%) on maintenance52immunosuppression, and in 4 patients (28.6%) on no
or minimal immunosuppression.
In patients with membranous nephropathy (patient
numbers 1, 10, 12, and 15), proteinuria in 1 patient (pa-
tient 1) completely resolved with conservative manage-
ment; 1 patient (patient 15; Supplementary Table S1) was
lost to follow-up and represented near ESRD, as above;
and 1 patient (patient 12) has had persistent nephrosis
(>3 g/d proteinuria) despite 3 months of steroid treat-
ment for associated IgG4-TIN. The ﬁnal patient (patient
10) had evidence of old membranous nephropathy on
biopsy, without clinically signiﬁcant proteinuria at the
time of presentation or during follow-up thereafter.
Malignancy and Mortality
One patient with IgG4-RKD or IgG4-RPF developed a
malignancy (basal cell carcinoma) after diagnosis. There
were no deaths.
The key ﬁndings and characteristics of patients
with renal and RPF involvement in this study are sum-
marized in Supplementary Tables S2 and S3, respectively,Kidney International Reports (2019) 4, 48–58
Table 3. Renal biopsy ﬁndings in patients with IgG4-RKD
Patient
number
Renal histology
overview: TIN,
glomerular
disease, both
Glomerular light
microscopy
abnormalities (aside
from focal sclerosis)
Glomerular deposits on
IF or EM
Tubulointerstitial light
microscopy: 1. LPC
inﬁltrate, 2. storiform
ﬁbrosis,
3. obliterative
phlebitis
IgG4D
plasma
cells/hpf
IgG4D/IgG,
%
LPC inﬁltrate patchy
or diffuse
TBM
deposits on
IF or EM
Fulﬁlls
Raissian TIN
criteria
1 Membranous
(no TIN)
Mesangial matrix
expansion,
thickened capillary
walls, spikes on
silver stain
IF: subepithelial IgG and
C3 (predominantly
IgG4), EM:
subepithelial deposits
Moderate ﬁbrosis, no
signiﬁcant
inﬂammatory cell
inﬁltrate
N/A N/A N/A No No
2 TIN Normal No LPC inﬁltrate and
ﬁbrosis
>10 >40% Diffuse TBM
deposits
on IF
Yes
3 TIN Normal No Scanty LPC inﬁltrate,
advanced ﬁbrosis
NR NR Patchy No No
4 TIN Normal No LPC inﬁltrate and
ﬁbrosis
>10 NR Diffuse No Yes
5 TIN Normal No LPC inﬁltrate and
ﬁbrosis
>10 NR Diffuse TBM
deposits
on IF
Yes
6 TIN Normal No LPC inﬁltrate and
ﬁbrosis
>10 NR Diffuse NR Yes
7 TIN NR NR LPC inﬁltrate and
ﬁbrosis
>10 NR Diffuse NR Yes
8 TIN Normal No Mild LPC inﬁltrate and
ﬁbrosis
>10 NR NR NR Yes
9 TIN Normal No LPC inﬁltrate and
ﬁbrosis
>10 NR NR No Yes
10 TIN,
membranous
(old)
Normal EM: small epithelial
spaces consistent with
resolved deposits in a
few capillary loops
(suggesting mild
membranous at some
stage)
LPC inﬁltrate and
ﬁbrosis
>10 >40% NR NR Yes
12 TIN,
membranous
Thickening basement
membranes with
spikes on silver
stain
Immunoperoxidase:
granular deposition
IgG and C9
LPC inﬁltrate >10 >40% Patchy NR Yes
13 TIN Normal No LPC inﬁltrate and
ﬁbrosis (mild)
>10 >40% Patchy NR Yes
14 TIN Shrunken glomeruli No LPC inﬁltrate and
ﬁbrosis (marked)
>10 >40% Patchy NR Yes
15 TIN,
membranous
Thickening of
Bowman capsule
and ischemic
wrinkling GBM.
Spikes on silver
stain.
IF: strongly positive
IgG4, and C3, in
glomerular basement
membrane. EM:
subepithelial deposits
LPC inﬁltrate,
storiform ﬁbrosis,
obliterative
phlebitis
>10 NR Diffuse Yes Yes
18 TIN 1 Crescent No LPC inﬁltrate and
ﬁbrosis
>10 >40% NR NR Yes
EM, electron microscopy; GBM, glomerular basement membrane; hpf, high-power ﬁeld; IF, immunoﬂuorescence; IgG4-RKD, IgG4-related kidney disease; LPC, lymphoplasmocytic; N/A,
not applicable; NR, not recorded; TBM, tubular basement membrane; TIN, tubulointerstitial nephritis.
RDR Evans et al.: IgG4-Related Kidney Disease in the UK CLINICAL RESEARCHand compared to those of previous cohorts of patients
with IgG4-RKD6–8,11 and IgG4-RPF.9,12–14DISCUSSION
We have described the clinicopathological characteris-
tics of IgG4-RKD and IgG4-RPF in a multicenter IgG4-
RD cohort from the UK. The prevalence of IgG4-RKD
was 11.7%, and the prevalence of IgG4-RPF was
9.1%. Patients were largely elderly men, with multi-
system features of IgG4-RD. Renal function was worseKidney International Reports (2019) 4, 48–58at presentation in those with intrinsic renal disease, and
complement was low in 50% of those with IgG4-RKD.
The predominant histological ﬁnding in IgG4-RKD was
IgG4-TIN; 27% of patients with renal biopsy had
membranous nephropathy. Most patients were treated
with steroids initially, with good response, although
46.4% of patients had an IgG4-RD relapse, most often
in the kidney. Steroid-sparing agents were used more
commonly to treat relapsed disease. Progressive renal
impairment occurred in 28.6% of patients on no
or minimal immunosuppression, with 2 patients53
Figure 3. Representative histology of IgG4-related tubulointerstitial nephritis (IgG4-TIN). (a) Hematoxylin and eosin stain demonstrating ﬁbrosis
and a dense inﬂammatory cell inﬁltrate rich in plasma cells and eosinophils with few small lymphocytes (original magniﬁcation 40). (b)
Storiform pattern of ﬁbrosis. (c) IgG stain. (d) IgG4 stain showing >30 IgG4þ plasma cells (high-power ﬁeld) (original magniﬁcation: b-d, 100).
CLINICAL RESEARCH RDR Evans et al.: IgG4-Related Kidney Disease in the UKreaching ESRD, 1 of whom underwent renal
transplantation.
Interpretation
Renal and RPF involvement in IgG4-RD has been
described in a number of general IgG4-RD cohorts in
Asia and the United States.21–30 Renal and retroper-
itoneal involvement was demonstrated in a median of
13% (range, 7%–44%) and 19% (range, 2%–32%) ofFigure 4. Hematoxylin and eosin stain demonstrating obliterative
phlebitis in a patient with IgG4-related retroperitoneal ﬁbrosis (IgG4-
RPF) (original magniﬁcation 200).
54patients across these studies. This compares to renal
and RPF involvement of 11.7% and 9.1% in our
cohort, respectively. Variation can be attributed to
criteria used to deﬁne renal and RPF involvement,
and the nature of the cohorts included. Regardless
of this, renal and retroperitoneal disease represent
major organ manifestations of IgG4-RD.Figure 5. Serum creatinine at baseline and posttreatment (at latest
review) in patients with IgG4-related kidney disease (IgG4-RKD)
(patient who underwent transplantation excluded).
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RDR Evans et al.: IgG4-Related Kidney Disease in the UK CLINICAL RESEARCHPresentation of IgG4-RKD and IgG4-RPF is varied, as
exempliﬁed by the vignettes (Supplementary Table S1)
of each case in this cohort. Symptoms may be related to
renal and RPF involvement themselves (e.g., nephrosis
in membranous nephropathy, back pain and leg
swelling due to impaired venous return in RPF), may
be related to other organ disease (most commonly
abdominal pain and jaundice with pancreatic/hep-
atobiliary disease in our cohort), or the disease may
present with an unexplained systemic illness (although
features of marked inﬂammation such as fever and
night sweats are rare). IgG4-RKD and IgG4-RPF may
become apparent during investigation of unexplained
renal impairment, may be an incidental ﬁnding on
imaging, or may be an unexpected histological ﬁnding,
often in cases of presumed cancer. Most patients have
multisystem disease; in this cohort and others, renal
disease rarely occurred alone.24
Renal function in patients with IgG4-RKD was
moderately impaired at presentation, (median creati-
nine 229 mmol/l), within the range reported in other
cohorts6–8 (147–318 mmol/l). Renal impairment is less
common in IgG4-RPF unless there is ureteric obstruc-
tion, particularly bilateral. Mild-to-moderate hemo-
proteinuria occurred in just over half of the patients
with IgG4-RKD; this was understandably more severe
in patients with glomerular disease.
Consistent with other cohorts of IgG4-RKD, most
patients had elevated serum IgG4 (not a universal
ﬁnding in IgG4-RD generally), and 50% had low
complement C3 or C4. IgG4 levels may not be elevated
in nephrotic syndrome, due to urinary loss of all Igs; in
this situation, we assess the ratio of serum IgG4 to total
IgG. Hypocomplementemia is more common in IgG4-
RKD than in other manifestations of IgG4-RD, and is
somewhat unexplained. The IgG4 subtype has limited
ability to ﬁx complement through the classical
pathway, and complement consumption may be the
result of increased activity of other Ig subtypes, IgG1
and IgG3, or through IgG4 complement activation via
the lectin pathway. Hypocomplementemia and TIN
(with or without glomerular disease) has been
described, albeit rarely, in primary Sjögren’s syndrome
(complement is maintained in most primary Sjögren’s
syndromeTIN patients), and such patients may also
have lacrimal and salivary gland disease.31,32 Although
antinuclear antibody is detectable in IgG4-RKD (35%
patients in this study), extractable nuclear antigens
are rare, whereas anti-SSA/Ro and anti-SSB/La anti-
gens are normally detectable in primary Sjögren’s
syndromeTIN.
Abnormalities on renal imaging were found in 61%
of patients with IgG4-RKD in this cohort: multiple low-
density lesions in 44%, and diffusely enlarged kidneysKidney International Reports (2019) 4, 48–58in 22%. These ﬁndings have been found in 40% to
46.5% and 4.9% to 30.4%, respectively, in previously
published IgG4-RKD cohorts.6–8 Thickening of the
renal pelvis is another reported ﬁnding in IgG4-RD,
but this was not seen in any patients in this study. CT
was the most common mode of renal imaging,
including PET-CT, which is increasingly used. Radia-
tion exposure, however, must be considered when
using these techniques, particularly given the associa-
tion of IgG4-RD and malignancy.16
Lymphoplasmocytic inﬁltration, with predomi-
nantly IgG4þ plasma cells (i.e. IgG4-TIN) with associ-
ated ﬁbrosis, was the most common renal biopsy
ﬁnding in our cohort, consistent with other series.
Plasma cells are polyclonal or oligoclonal, distinguish-
ing it from lymphomatous inﬁltration of the kidney,
and granulomatous inﬂammation is not reported (this
feature points more toward other causes of TIN,
including sarcoid, tuberculosis, or a granulomatous
form of drug-induced TIN).33 Unlike ﬁbrosis in other
organs, the characteristic storiform pattern was seen
less commonly in the kidney, and similarly obliterative
phlebitis, a feature of IgG4-RD at other sites, was rare.
Tubular immune deposits may occur in up to 83% of
patients with IgG4-TIN.6 Tubular immunostaining or
electron microscopy was performed and reported in
only a minority of our historical biopsy results; tubular
deposits were present in 75% of cases when it
occurred.
TIN may be accompanied by glomerular disease,
in 9% to 39% of cases from previous reports, and in
27% of biopsy results in our series. All glomerular
disease in this study was membranous nephropathy,
the most common glomerular disease associated with
IgG4-RD,34 but other patterns have been reported
including IgA nephropathy and mesangioprolifer-
ative and membranoproliferative glomerulone-
phritis.6,10 Unlike the majority of patients with
primary membranous nephropathy, patients with
IgG4-RD do not have detectable antibodies to the
phospholipase A2 receptor (PLA2R)35; antibodies to
other podocyte antigens, such as carbonic anhy-
drase II, have been described.36 Notably, as
occurred in 1 patient in our series, membranous
nephropathy may occur without associated TIN,
and therefore a diagnosis of IgG4-RD should be
considered in patients with membranous nephrop-
athy without other obvious cause, particularly if
anti-PLA2R negative.
There are no randomized controlled studies to guide
the management of IgG4-RD. Lymphoplasmocytic
inﬁltration (including IgG4-TIN and IgG4-RPF) is
usually quickly responsive to steroid, and the majority
of patients in this and other cohorts were treated with55
CLINICAL RESEARCH RDR Evans et al.: IgG4-Related Kidney Disease in the UKoral prednisolone (mean starting dose 40 mg/d in this
study) ﬁrst line. Whether to use a steroid-sparing agent
as part of therapy is less clear. Renal function improved
in most patients, but, as demonstrated by cases in this
and other studies, IgG4-RD is often a relapsing disease
(46.4% of our patients relapsed, most often in the
kidney), which may lead to progressive and permanent
organ damage (11.1% with IgG4-RKD reached ESRD).
Steroid therapy has a plethora of unwanted side effects
(e.g., worsening diabetes including insulin depen-
dence, and osteoporotic crush fractures in our cohort),
and the use of a steroid-sparing agent permits longer-
term immunosuppression, while avoiding these.37
Steroid-sparing agents were used in 16% of patients
as part of initial therapy and in 54% patients with
relapsed disease in this study; an antiproliferative
(azathioprine or mycophenolate mofetil) or rituximab
was used. Combined therapy with rituximab and
cyclophosphamide has recently been reported in IgG4-
RKD with good outcomes in a small number of pa-
tients.38 Future management will depend on patient
stratiﬁcation combined with close follow-up to identify
those patients more likely to progress toward ESRD,
and in whom more intensive therapy may be beneﬁcial.
The development of national and international IgG4-RD
registries, such as the European Association for the
Study of the Liver (EASL) IgG4-RD Registry, is an
essential part of enabling this process.39
Unlike lymphoplasmocytic inﬂammation, there are no
data to suggest that membranous nephropathy in IgG4-
RD is steroid responsive; we approach membranous in
IgG4-RD in the same way as we manage primary mem-
branous nephropathy. One patient underwent trans-
plantation in our cohort; IgG4-RD recurrence has
recently been reported in a renal allograft,40 but whether
immunosuppression protocols should be modiﬁed in
patients with IgG4-RD undergoing transplantation is
unknown.
Strengths and Limitations
This study is the ﬁrst to report the clinical, radio-
logical, and pathological features of renal and retro-
peritoneal involvement in a UK cohort of IgG4-RD
patients. It included patients from multiple centers,
with follow-up data in most. We have compared our
ﬁndings to other major cohorts of IgG4-RKD and
IgG4-RPF patients, largely reported from North
America and Asia. The LondonOxford IgG4-RD
cohort was established by gastroenterologists, and
therefore pancreatohepatobiliary disease may be
overrepresented and renal or urological disease un-
derrepresented. The retrospective nature of the study
means that data may be affected by recall bias, and
some data are missing. This includes ethnicity, and56details of IgG4 and complement levels before and af-
ter initiation of therapy, particularly in patients with
IgG4-RPF, and therefore comparisons in these and
other parameters between IgG4-RKD and IgG4-RPF
patients were difﬁcult to make. Precise details of
IgG4 staining (e.g., number of IgG4þ cells) and the
pattern of ﬁbrosis (i.e., storiform or not) were not
always reported, and not all renal biopsy specimens
could be re-reviewed or re-stained. Similarly, details
of immunoﬂuorescence and electron microscopy,
particularly tubular, were available only in a minor-
ity of patients.
In conclusion, IgG4-RKD and IgG4-RPF represent
major organ manifestations of IgG4-RD, and the
characteristics of patients within the UK are similar
to those of patients in other parts of the world. The
predominant renal manifestations are IgG4-TIN and
IgG4-related membranous nephropathy. Although
most patients responded to immunosuppressive
therapy, IgG4-RKD frequently relapsed, and the role
of steroid-sparing agents as part of initial mainte-
nance therapy needs to be established. End-stage
renal disease may occur, in particular with delayed
presentation or without treatment. Transplantation
may be undertaken in IgG4-RD patients, but long-
term outcomes in these patients are yet to be
determined.
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